New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Marie-Claire Seeley

Dr Marie-Claire Seeley

Postural Orthostatic Tachycardia Syndrome in Women

Dr Charlotte Hespe & Dr Ramy Bishay

Dr Charlotte Hespe & Dr Ramy Bishay

Panel Discussion on The Role of GLP-1 in the Management of CKD in T2D

Dr Anthony Chitti

Dr Anthony Chitti

Big Heads & Small Heads

Dr Sam Mehr

Dr Sam Mehr

Peanut Allergy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023